FDA Issues Nationwide Recall of Over 7,000 Bottles of Duloxetine Due to Cancer-Causing Chemical

The U.S. Food and Drug Administration (FDA) has announced a nationwide recall of more than 7,000 bottles of duloxetine delayed-release capsules. This recall is prompted by the presence of N-nitroso-duloxetine, a chemical that has been identified as potentially cancer-causing.

Duloxetine, which is sold under the brand name Cymbalta, is commonly used to treat depression, anxiety, and certain types of pain. The affected bottles were found to contain high levels of the carcinogenic chemical, leading the FDA to classify this as a Class II recall.

Healthcare professionals and patients are advised to immediately stop using the recalled medication and return any unused portions to the manufacturer. The FDA is working closely with the manufacturer to ensure all affected products are removed from the market and to prevent any further distribution.

This recall underscores the importance of rigorous quality control measures in pharmaceutical manufacturing to protect public health. Patients who have been prescribed duloxetine should consult their healthcare providers for alternative treatments and to discuss any concerns related to this recall.